Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Revenio Group Oyj
  6. News
  7. Summary
    REG1V   FI0009010912

REVENIO GROUP OYJ

(REG1V)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Revenio Group Corporation: Invitation to Revenio's audiocast and teleconference in relation to the half-year financial report 2021

07/27/2021 | 02:01am EDT

Revenio Group Corporation, Press release, July 27, 2021 at 9.00

Invitation to Revenio’s audiocast and teleconference in relation to the half-year financial report 2021

Revenio Group Corporation’s half-year financial report 2021 on Thursday, 5 August 2021, approximately at 9:00 am.

An audiocast and teleconference for analytics and investors is held in English at 3:00 pm on the same day.

Link to the event: https://revenio.videosync.fi/2021-08-05-revenioq2

Teleconference numbers:
FI: +358 981710310
SE: +46 856642651
UK: +44 3333000804
US: +1 6319131422

PIN: 40296342#

For further information, please contact:
Robin Pulkkinen, CFO, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi
https://www.reveniogroup.fi/en/

Revenio Group in brief
Revenio is a leading company in ophthalmological devices and software solutions. Revenio Group’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), retinal imaging devices, and perimeters under the iCare brand. In addition, the Group’s eye care software platform Oculo brings together clinical communication, telehealth, remote patient monitoring, and data analytics capabilities.

Revenio Group comprises Revenio Group Corporation, Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Revenio Australia Pty Ltd, Done Medical Oy and Oscare Medical Oy.

In 2020, the Group’s net sales totaled EUR 61.1 million and its operating profit amounted to EUR 17.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

© Modular Finance, source Nordic Press Releases

All news about REVENIO GROUP OYJ
02:01aREVENIO OYJ : Group Corporation - Managers' Transactions
AQ
08/05REVENIO GROUP CORPORATION : Half-year financial report 1 January-30 June 2021
AQ
08/05Revenio Group Oyj Reports Earnings Results for the Second Quarter Ended June ..
CI
08/04REVENIO GROUP CORPORATION : Revenio updates its financial guidance for 2021
AQ
08/04Revenio Group Corporation Reaffirms Earnings Guidance for the Full Year 2021
CI
07/27REVENIO GROUP CORPORATION : Invitation to Revenio's audiocast and teleconference..
AQ
06/18REVENIO GROUP CORPORATION : Hanna Vuornos appointed Director, People&Culture and..
AQ
06/18Revenio Group Corporation Appoints Hanna Vuornos as Director, People&Culture ..
CI
06/15REVENIO GROUP CORPORATION : Increased number of shares entered into trade regist..
AQ
05/28REVENIO GROUP CORPORATION : Transfer of the Company's own shares
AQ
More news
Financials
Sales 2021 77,9 M 91,3 M 91,3 M
Net income 2021 17,4 M 20,4 M 20,4 M
Net Debt 2021 1,60 M 1,87 M 1,87 M
P/E ratio 2021 92,4x
Yield 2021 0,57%
Capitalization 1 611 M 1 891 M 1 887 M
EV / Sales 2021 20,7x
EV / Sales 2022 17,2x
Nbr of Employees 167
Free-Float 86,2%
Chart REVENIO GROUP OYJ
Duration : Period :
Revenio Group Oyj Technical Analysis Chart | REG1V | FI0009010912 | MarketScreener
Technical analysis trends REVENIO GROUP OYJ
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 60,65 €
Average target price 63,17 €
Spread / Average Target 4,15%
EPS Revisions
Managers and Directors
Jouni Erik Toijala President & Chief Executive Officer
Robin Allan Pulkkinen Chief Financial Officer
Pekka Veikko Juhani R÷nkń Chairman
Mika Salkola Director-Research & Development
Ari Isomńki Operations Director
Sector and Competitors
1st jan.Capi. (M$)
REVENIO GROUP OYJ20.58%1 891
SARTORIUS AG96.23%49 859
BIOTAGE AB (PUBL)85.90%1 940
CELLAVISION AB (PUBL)45.02%1 223
VAREX IMAGING CORPORATION73.38%1 140
ANGLE PLC149.21%384